Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patriarca

Showing results (941-950 of 1,012) with videos related to

Pageof 102
Sort By:
The New England Journal of Medicine|January 7, 2016
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host DiseaseNicolaus Kröger, Carlos Solano, Christine Wolschke, et al.
Science (New York, N.Y.)|May 13, 2017
The extent of forest in dryland biomesJean-François Bastin, Nora Berrahmouni, Alan Grainger, et al.
Immunobiology|January 22, 2020
Human B cells infected by Trypanosoma cruzi undergo F-actin disruption and cell death via caspase-7 activation and cleavage of phospholipase Cγ1Marlus Alves Dos Santos, Flávia Alves Martins, Bruna Cristina Borges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2022
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO NetworkRaphael Itzykson, Valeria Santini, Sylvain Thepot, et al.
Blood Cancer Journal|August 21, 2024
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trialGianluca Cavallaro, Anna Grassi, Chiara Pavoni, et al.
Leukemia|March 8, 2024
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE studyAnnalisa Chiappella, Beatrice Casadei, Patrizia Chiusolo, et al.
Nature Medicine|March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
The Lancet. Haematology|February 3, 2019
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised studyFrancesca Bonifazi, Carlos Solano, Christine Wolschke, et al.
European Journal of Haematology|July 20, 2024
Evans syndrome: Disease awareness and clinical management in a nation-wide ITP-NET surveyBruno Fattizzo, Valentina Carrai, Monica Crugnola, et al.
Haematologica|January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trialFriedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Pageof 102

Showing results (941-950 of 1,012) with videos related to

Sort By:
Pageof 102
The New England Journal of Medicine|January 7, 2016
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host DiseaseNicolaus Kröger, Carlos Solano, Christine Wolschke, et al.
Science (New York, N.Y.)|May 13, 2017
The extent of forest in dryland biomesJean-François Bastin, Nora Berrahmouni, Alan Grainger, et al.
Immunobiology|January 22, 2020
Human B cells infected by Trypanosoma cruzi undergo F-actin disruption and cell death via caspase-7 activation and cleavage of phospholipase Cγ1Marlus Alves Dos Santos, Flávia Alves Martins, Bruna Cristina Borges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2022
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO NetworkRaphael Itzykson, Valeria Santini, Sylvain Thepot, et al.
Blood Cancer Journal|August 21, 2024
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trialGianluca Cavallaro, Anna Grassi, Chiara Pavoni, et al.
Leukemia|March 8, 2024
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE studyAnnalisa Chiappella, Beatrice Casadei, Patrizia Chiusolo, et al.
Nature Medicine|March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
The Lancet. Haematology|February 3, 2019
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised studyFrancesca Bonifazi, Carlos Solano, Christine Wolschke, et al.
European Journal of Haematology|July 20, 2024
Evans syndrome: Disease awareness and clinical management in a nation-wide ITP-NET surveyBruno Fattizzo, Valentina Carrai, Monica Crugnola, et al.
Haematologica|January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trialFriedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Pageof 102